ISRCTN90051516
Completed
N/A
Modification of vascular disease markers in active rheumatoid arthritis with fully human monoclonal anti-TNF-alpha antibody (Humira® [adalimumab])
Guy's and St Thomas' NHS Foundation Trust (UK)0 sites24 target enrollmentFebruary 14, 2008
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Rheumatoid arthritis
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust (UK)
- Enrollment
- 24
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Subjects who fulfill the British Society of Rheumatology guidelines for TNF blocking therapy in Rheumatoid Arthritis (RA)
- •2\. Subjects who have abnormal vascular function as assessed at the screening visit
- •3\. Men and women \>\= 18 years of age, with RA as defined by the 1987\-revised merican College of Rheumatology (ACR) diagnostic criteria, with a Disease Activity Score (DAS) greater than 5\.1
- •4\. Men and women of childbearing potential must use adequate birth control measures (e.g., abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, or surgical sterilization) for the duration of the study
- •5\. Patient must be able to adhere to the study visit schedule
- •6\. The patient must be capable of giving informed consent and the consent must be obtained prior to any screening procedures
- •7\. Must have a chest X\-ray within 3 months prior to commencement of adalimumab with no evidence of malignancy, infection or fibrosis
Exclusion Criteria
- •1\. Women who are pregnant or breast feeding.
- •2\. Use of any investigational drug within 1 month prior to screening or within 5 half\-lives of the investigational agent, whichever is longer.
- •3\. Treatment with any other therapeutic agent targeted at reducing TNF (e.g., pentoxifylline, thalidomide, etanercept, etc.) within 3 months of screening.
- •4\. History of diabetes mellitus.
- •5\. History of ischemic heart disease or peripheral vascular disease.
- •6\. Serious infections (such as pneumonia or pyelonephritis) in the previous 3 months. Less serious infections (such as acute upper respiratory tract infection \[colds] or simple urinary tract infection) need not be considered exclusions at the discretion of the investigator.
- •7\. Have active TB or have evidence of latent TB (old or latent TB on chest x\-ray, without adequate therapy for TB initiated prior to first dose of study drug). Also excluded are patients with evidence of an old or latent TB infection without documented adequate therapy. Patients with a current close contact with an individual with active TB and patients who have completed treatment for active TB within the previous 2 years are explicitly excluded from the trial. Patients with a household member who has a history of active pulmonary TB should have had a thorough evaluation for TB prior to study enrollment as recommended by a local infectious disease specialist or published local guidelines of TB control agencies.
- •8\. Presence of a transplanted organ (with the exception of a corneal transplant \>3 months prior to screening).
- •9\. Malignancy within the past 5 years (except for squamous or basal cell carcinoma of the skin that has been treated with no evidence of recurrence).
- •10\. History of lymphoproliferative disease including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy of unusual size or location (such as nodes in the posterior triangle of the neck, infra\-clavicular, epitrochlear, or periaortic areas), or splenomegaly.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
N/A
The study of biomarkers for intractable vascular anomalies and associated with pharmacological action of sirolimusVascular anomaliesJPRN-UMIN000029173Gifu University50
Not Yet Recruiting
N/A
Development of risk indicators for vascular diseases with multi-omics and non-invasive blood flow analysis1.Diabetes and its complications 2.Vascular diseasesJPRN-UMIN000039800Tohoku University7,000
Completed
N/A
Relevance of Vascular Function Markers: Study on the Effects of Quercetin and Epicatechin on Blood Pressure and Vascular Function in (Pre)Hypertensive SubjectsHigh blood pressurevascular function10057166NL-OMON39481TI Food and Nutrition40
Recruiting
N/A
The relation between inflammation cells and immune-system cells and the development of hardening of the arteries (arteriosclerosis), a research project with MRI in young adultsdevelopment of subclinical arteriosclerosis in the young de ontwikkeling van subklinische atherosclerose in jonge volwassenenNL-OMON27711niversity Medical Center Utrecht520
Completed
N/A
Biomarkers and cardiovascular risk in disease models of non-alcoholic fatty liver diseaseNL-OMON48654Medisch Universitair Ziekenhuis Maastricht85